Working together to cut costs and improve patient outcomes worldwide

Cardiovascular disease (CVD) is responsible for nearly one of every three deaths per year 1. Most people don’t have symptoms before their first heart attack2. This is why CVD is known as “the silent killer.”
Until the AngioDefender system, measuring damage to your arteries required highly technical, expensive, and often invasive procedures. Now you can receive an accurate, non-invasive assessment of your vascular health and overall risk of CVD in just minutes.


Highly accurate: computerized procedure generates reliable data
Quick: test conducted in under 20 minutes
Non-invasive: uses a blood pressure cuff
Instant results: report available immediately


If you are already a partner of Everist Health™, welcome back.


New Partners

Everist Health™ is seeking distribution for markets worldwide. If you would like more information regarding the AngioDefender® system or would like to schedule a demonstration please contact us using the form below.

Note: Although the AngioDefender system is not commercially available in the United States, please fill out the Request Information Form below if you are interested in United States distribution.  Subscribe to our e-newsletter for important regulatory updates


  1.; World Health Organization fact sheet. 2013.
  2. In fact, many studies show that up to 64% of all heart attack victims under 60 years of age experience no symptoms prior to their first attack. Valensi et al. Prevalence, incidence, predictive factors and prognosis of silent myocardial infarction: A review of the literature. Arch Cardio Dis 2011; 104:178-8.

View our Clinical Insert Pamphlet for more info.(pdf)

View our Clinical Validation or our CE Mark Certificate for more info (pdf)

View our PATIENT FLYER for more info (pdf)

Learn more about what we can do for you